114 related articles for article (PubMed ID: 38557522)
21. Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience.
Santiago RJ; Harris EE; Qin L; Hwang WT; Solin LJ
Cancer; 2005 Jun; 103(12):2447-54. PubMed ID: 15887223
[TBL] [Abstract][Full Text] [Related]
22. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
23. Reduced clinicopathological influence of hormone-dependence on breast carcinomas in women older than 70 years.
Ruibal A; Sánchez Salmón A
Int J Biol Markers; 2008; 23(1):58-62. PubMed ID: 18409153
[TBL] [Abstract][Full Text] [Related]
24. Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.
Cutuli B; Dalenc F; Cottu PH; Gligorov J; Guastalla JP; Petit T; Amrate A
Cancer Radiother; 2015 Aug; 19(5):295-302. PubMed ID: 26188735
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG; Lacey JV; Carreon JD; Hoover RN
J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological stages of carcinoma breast patient.
Mohiuddin M; Gafur MA; Karim MR; Khan SA; Hoque MM; Islam MS; Ali MS
Mymensingh Med J; 2012 Apr; 21(2):238-45. PubMed ID: 22561765
[TBL] [Abstract][Full Text] [Related]
27. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer in Chinese elderly women: pathological and clinical characteristics and factors influencing treatment patterns.
Ma CD; Zhou Q; Nie XQ; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen KW; Shen ZZ
Crit Rev Oncol Hematol; 2009 Sep; 71(3):258-65. PubMed ID: 19150602
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
30. Triple-negative breast cancer and obesity in a rural Appalachian population.
Vona-Davis L; Rose DP; Hazard H; Howard-McNatt M; Adkins F; Partin J; Hobbs G
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3319-24. PubMed ID: 19064545
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population.
Lim ST; Yu JH; Park HK; Moon BI; Ko BK; Suh YJ
World J Surg Oncol; 2014 Mar; 12():56. PubMed ID: 24621330
[TBL] [Abstract][Full Text] [Related]
32. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.
Gokce H; Durak MG; Akin MM; Canda T; Balci P; Ellidokuz H; Demirkan B; Gorken IB; Sevinc AI; Kocdor MA; Saydam S; Harmancioglu O
Breast J; 2013; 19(4):374-81. PubMed ID: 23714006
[TBL] [Abstract][Full Text] [Related]
33. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
34. Invasive Ductal Carcinoma: Correlation of Immunophenotypic Features with Age.
Lateef F; Jamal S; Nasir S; Jamil Z
J Coll Physicians Surg Pak; 2017 Jan; 27(1):18-22. PubMed ID: 28292362
[TBL] [Abstract][Full Text] [Related]
35. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
36. Triple-negative breast cancer in West Virginia.
Abraham J; Flanagan M; Hazard H; Jubelirer S; Tirona MT; Vona-Davis L
W V Med J; 2009 Oct; 105 Spec No():54-9. PubMed ID: 19999267
[TBL] [Abstract][Full Text] [Related]
37. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
38. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
Grann VR; Troxel AB; Zojwalla NJ; Jacobson JS; Hershman D; Neugut AI
Cancer; 2005 Jun; 103(11):2241-51. PubMed ID: 15844176
[TBL] [Abstract][Full Text] [Related]
39. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes.
Winchester DJ; Chang HR; Graves TA; Menck HR; Bland KI; Winchester DP
J Am Coll Surg; 1998 Apr; 186(4):416-22. PubMed ID: 9544955
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011.
Kadivar M; Mafi N; Joulaee A; Shamshiri A; Hosseini N
Asian Pac J Cancer Prev; 2012; 13(5):1881-6. PubMed ID: 22901141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
